Saniona announces decisions from the 2026 Annual General Meeting
The meeting approved the accounts, re-election of the board and rejection of two proposals due to shareholder opposition.
See the latest news and media coverage for Saniona. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing ion channel modulators
saniona.comLast updated
In short: Saniona expanded its epilepsy pipeline through major licensing deals with Jazz Pharmaceuticals and Acadia Pharmaceuticals while advancing SAN2668.
The meeting approved the accounts, re-election of the board and rejection of two proposals due to shareholder opposition.
SAN2668 addresses sedation, cognitive impairment, and tolerance. The company advances three programs to Phase 2 and initiates preclinical development for Phase 1 in 2026.
The call occurs on 28 August at 13:00 CET. Management presents results, updates, and hosts a Q&A session.
Saniona receives $42.5 million upfront plus potential milestones and royalties for SAN2355.
Saniona's figures for the first quarter of 2026 reflect a company shifting from validation to practical clinical implementation. Revenues amounted to SEK 4.7 million (9.8), the operating loss widened...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it has entered into an exclusive worldwide license agreement with Saniona (OMX: SANION) for the development and commercialization...
Saniona’s performance in 2025 was driven by the strategically important agreements secured with Jazz Pharmaceuticals in 2025 and Acadia Pharmaceuticals in 2024. Together, these have...
Saniona AB (FRA:30S) strengthened its financial position in 2025, ending the year with approximately 581 million crowns in cash. The company secured significant pharmaceutical partnerships...
Track Saniona and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Saniona and other trending companies.